gastric cancer
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
February 4, 2026Research and Development Astellas Pharma, Scottish Medicines Consortium, Vyloy, gastric cancer, oncology
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that Vyloy (zolbetuximab), in combination with …
New gastric & gastro-oesophageal junction cancer treatment VYLOYâ„¢ â–¼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
Merck’s Keytruda approved by EC for gastric cancer
August 30, 2023Research and Development EC, Merck, Oncology, gastric cancer, keytruda
Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …
Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans
December 11, 2017Research and Development, Sales and Marketing Cancer, Eli Lilly, cyramza, gastric cancer, pharma
Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
Erbitux fails in gastric cancer trial
July 6, 2012Research and Development, Sales and Marketing Erbitux, Merck Serono, Roche, failure, gastric cancer
Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to …
NICE recommends Herceptin for gastric cancer, blocks high dose Glivec
November 24, 2010Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer
NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …
NICE set to block Herceptin for gastric cancer
July 6, 2010Sales and Marketing Herceptin, NICE, Roche, gastric cancer
NICE’s preliminary draft guidance has not approved Roche’s Herceptin for gastric cancer as it failed to show how far the …
Avastin fails in phase III study
February 24, 2010Research and Development Roche, avastin, gastric cancer, stomach cancer
Roche’s Avastin does not help patients with a severe form of stomach cancer to live longer, according to the results …
Roche expands Herceptin franchise
February 8, 2010Sales and Marketing Herceptin, Roche, gastric cancer, stomach cancer
Roche’s blockbuster breast cancer treatment Herceptin has been launched in the UK as a treatment for stomach cancer. It is …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
